(A) CXCL12 release measured in Hut-78, H9, HH and PBMC cells incubated 24 hours with 0, 10, and 100 nM BZ. Asterisks denote a statistically significant (p<0.05) change compared to untreated cells. (B) CXCL12 release measured in HH cells transfected with control or TGFβ1 specific siRNA, and incubated 24 hours with 0, 10, and 100 nM BZ. (C) CXCL12 release measured in control and TGFβ1 siRNA transfected HH cells, and incubated 24 hours with 0, 200 and 400 pg/ml of exogenously added recombinant TGFβ1. (D) Migration assay of HH cells incubated 6 hours with 300 ng/ml of TGFβ neutralizing antibody (empty columns) or control IgG (full columns) in the absence and presence of 50 ng/ml of CXCL12 added to the lower chamber. The values represent the mean +/−SE of four experiments; asterisks denote a statistically significant (p<0.05) change compared to cells incubated with control antibody.